In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
about
Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazolePharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsA sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatusGenetic Analysis Using an Isogenic Mating Pair of Aspergillus fumigatus Identifies Azole Resistance Genes and Lack of MAT Locus's Role in VirulenceTreatment of cryptococcosis in the setting of HIV coinfection.Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cellMultilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.A five-year survey of dematiaceous fungi in a tropical hospital reveals potential opportunistic speciesSteady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey.Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance programAntifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles.Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex.Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients.In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study.Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.The Ssk1p response regulator and Chk1p histidine kinase mutants of Candida albicans are hypersensitive to fluconazole and voriconazole.Treatment with intrastromal and intracameral voriconazole in 2 eyes with Lasiodiplodia theobromae keratitis: case reports.Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2.Developments in the treatment of candidiasis: more choices and new challenges.Role of posaconazole in the management of oropharyngeal and esophageal candidiasisPosaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature.In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.Posaconazole: a new broad-spectrum antifungal agent.Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex.Candidiasis in Pediatrics; Identification and In vitro Antifungal Susceptibility of the Clinical IsolatesBioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis.Is azole resistance in Aspergillus fumigatus a problem in Spain?Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.Posaconazole in the management of refractory invasive fungal infections.Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.Fusarium infection in lung transplant patients: report of 6 cases and review of the literature.Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
P2860
Q26782472-AC431E42-3481-4954-BE55-CF3159C18DCBQ27025299-6F7B4BB6-63DF-40DA-BED5-11117319B9A2Q28473962-A7C5136C-B15A-44A9-ABD8-675DC769E655Q28546712-CD7A4475-AC77-433D-B864-0F5950F56C50Q30366117-21D6AAF3-08F7-4809-82CA-890DF8F48454Q33315163-4591696C-D866-47E1-87EF-E8EB86F9D487Q33622915-6E3A3679-3BF8-4BEA-B560-EC0A98959D89Q33798313-2669E60B-E000-44B7-AB7E-3057EED37F43Q34011074-756BFD46-0F17-448E-AD66-E02D9DD7F7D8Q34108650-750AC36C-2FEF-4AA9-9CA6-184C35F6B4F3Q34187936-FE452797-2F39-42F4-96A0-FCB800279B45Q35067016-10232843-9156-4EF5-8B0F-6EE8EB74B08CQ35110919-CB9879E6-E097-4B65-A634-D72F4EB52D51Q35533576-87D250FB-315A-4B36-833D-AB11CF01288AQ35668229-94B57D43-FD41-4EC4-9E49-21E30954B24FQ35715408-A05D6480-F13C-4188-B8AA-DCF101642196Q35759094-D3298F49-4BE7-49D4-BC08-AEC26D99CA90Q35806236-E6B98097-0AB1-484B-848F-088C2F90E124Q35899223-91687EE4-A5D8-409E-8836-1ACB03D26C89Q35941414-923EADF1-E2A5-422B-8834-F04D6C2DAE10Q36018743-9E213980-EB98-4711-BD7D-3A1B97DEFC54Q36094852-438C5197-7886-474D-B2C7-78338A2D5B4BQ36095050-2586256F-DB73-4BBC-AAFD-8069FFA0C0CEQ36152402-7CB0EAAE-89FE-4B36-B814-1865406E8F03Q36396182-310BEBC2-AA47-4F42-A3BC-A6FBF6AFC704Q36623050-EC4837DE-DB5C-4759-853F-1A0B1416540DQ36642964-B7493279-1C65-43A7-94F3-C70A70D672ABQ36718486-43AB77E2-1651-4614-AA08-148BF1CC9990Q36803960-6C97219D-E2BA-4690-9036-BD71534F3775Q36828159-DFA9BB5E-6A3D-4293-8DEC-7E819BB030CEQ36845419-95EDFACE-BBBB-4D40-8EEC-D5B8F1F61F5EQ36901716-710C1908-D630-4CB2-B6D8-46EF5440A527Q36974215-8F86B4E2-A311-41EF-AD9F-0E19359CE6EBQ37026702-6349069D-5F42-4A8E-8C37-C211F4768733Q37048679-185F0FDA-9DF1-4EDE-B7B2-D951DE9076F5Q37052755-C4D3F809-B8C7-47F8-B253-FDF701542E81Q37055215-2A9E7FA1-823B-4B54-8346-F33F72DAAC00Q37072036-EE8FB195-9712-4854-A5E0-434ADE302AB6Q37114436-676B7109-8158-4768-9086-5E25EC2746A5Q37115829-C834C93B-A1FD-42C6-8AB9-4E7CEAE7CED4
P2860
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
In vitro activities of posacon ...... ly important molds and yeasts.
@ast
In vitro activities of posacon ...... ly important molds and yeasts.
@en
In vitro activities of posacon ...... ly important molds and yeasts.
@nl
type
label
In vitro activities of posacon ...... ly important molds and yeasts.
@ast
In vitro activities of posacon ...... ly important molds and yeasts.
@en
In vitro activities of posacon ...... ly important molds and yeasts.
@nl
prefLabel
In vitro activities of posacon ...... ly important molds and yeasts.
@ast
In vitro activities of posacon ...... ly important molds and yeasts.
@en
In vitro activities of posacon ...... ly important molds and yeasts.
@nl
P2093
P2860
P356
P1476
In vitro activities of posacon ...... ly important molds and yeasts.
@en
P2093
C A Mendrick
C C Norris
D Loebenberg
F Sabatelli
P M McNicholas
P2860
P304
P356
10.1128/AAC.00163-06
P407
P577
2006-06-01T00:00:00Z